POSA411 Real World Outcomes of First Line Pembrolizumab Monotherapy for Advanced PD-L1 Positive Non-Small Cell Lung Cancer

Abstract

Authors

R Chu A Vegas C Gorry D Power

Full Text Cite This Article
Back to ISPOR Europe 2021 Abstracts: Emerging Frontiers and Opportunities
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×